✦ LIBER ✦

Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design

✍ Scribed by Hotho, Daphne M; de Bruijne, Joep; O’Farrell, A Marie; Boyea, Teresa; Li, Jianke; Bracken, Michele; Li, Xin; Campbell, David; Guler, Hans-Peter; Weegink, Christine J

Book ID: 115525199
Publisher: International Medical Press
Year: 2011
Tongue: English
Weight: 495 KB
Volume: 17
Category: Article
ISSN: 1359-6535
DOI: 10.3851/imp1989

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

768 IN VITRO ANTIVIRAL ACTIVITY OF IDX32

768 IN VITRO ANTIVIRAL ACTIVITY OF IDX320, A NOVEL AND POTENT MACROCYCLIC HCV PROTEASE INHIBITOR

✍ L.B. Lallos; J. Mccarville; B. Li; J.P. Bilello; M. Lacolla; J. Jakubik; M.A. So 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 68 KB

2003 ANTIVIRAL ACTIVITY, PHARMACOKINETIC

2003 ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS

✍ Gane, E.; Foster, G.R.; Cianciara, J.; Stedman, C.; Ryder, S.; Buti, M.; Clark, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 100 KB

941 JTK-652 IS A NOVEL HCV ENTRY INHIBIT

941 JTK-652 IS A NOVEL HCV ENTRY INHIBITOR: RESULTS OF A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY IN CHRONIC HEPATITIS C PATIENTS

✍ J. de Bruijne; J. Bergmann; C. Weegink; K. van Nieuwkerk; R. de Knegt; J. van de 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

64 SAFETY OF THE HCV PROTEASE INHIBITOR

64 SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY

✍ H. Reesink; R. Verloes; K. Abou Farha; A. Van Vliet; C. Weegink; G. van 't Kloos 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB

1046 FIRST-IN-MAN DEMONSTRATION OF POTEN

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

✍ Gane, E.J.; Roberts, S.K.; Stedman, C.; Angus, P.W.; Ritchie, B.; Elston, R.; Ip 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 96 KB

A phase I trial of the pharmacokinetics,

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection

✍ Rachel W. Humphrey; Kathleen M. Wyvill; Bach-Yen Nguyen; Laura E. Shay; David R. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 143 KB